Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Executive Summary

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

You may also be interested in...



Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe

Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.

As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise

While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.

Endo’s Next Chapter Will Be Led By CEO De Silva

Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS056718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel